Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

116.83 +0.23 (+0.20%)
Official Closing Price Updated: 4:10 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
33 34 Next >
(ABT) - Analyzing Abbott Laboratories's Short Interest
Via Benzinga
GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations
Morgan Stanley analyst Patrick Wood initiated coverage on GE HealthCare Technologies Inc (NASDAQ: GEHC) with an Equal-Weight rating and a  
Via Benzinga
Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market
The company makes continuous glucose monitors for patients with diabetes. 
Via Investor's Business Daily
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval
The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device  
Via Benzinga
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
Via Benzinga
3 Passive Income Stocks to Hold for the Next 20 Years
These three stocks are likely to keep increasing their dividends over years or even decades. 
Via The Motley Fool
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application
In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte 
Via Benzinga
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Recent troubles won't stop these companies' long-term trajectories. 
Via The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories
Benzinga 
Via Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
Abbott Laboratories Unusual Options Activity For May 10
Via Benzinga
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
Via Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had... 
Via Benzinga
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' < 
Via Benzinga
Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices
The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as  
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories
A New York City woman has reportedly sued Abbott Laboratories (NYSE: ABT), accusing them of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase... 
Via Benzinga
Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks
Here are seven must-have dividend stocks for long-term investing that you can consider for your dividend stock portfolio. 
Via InvestorPlace
Cramer Asks Investors To Focus On Individual Stocks Over Macro Strategies: Says Don't 'Miss The Trees For The Forest'
Via Benzinga
3 Dividend Stock Warning Signs That Could Portend Trouble
Recognizing these red flags will help you avoid investing in weaker businesses. 
Via The Motley Fool
Is Dexcom a Good Stock to Buy Now?
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it. 
Via The Motley Fool
3 Stocks to Buy Before They Soar to New Heights in 2023
Here are three stocks to buy, for investors looking for companies on the cusp of a potential breakout driven by secular growth catalysts. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.